Journal article
Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel), a Phase III clinical trial on stereotactic ablative body radiotherapy of early stage lung cancer
T Kron, B Chesson, N Hardcastle, M Crain, N Clements, M Burns, D Ball
British Journal of Radiology | BRITISH INST RADIOLOGY | Published : 2018
DOI: 10.1259/bjr.20170737
Abstract
Objective: A randomised clinical trial comparing stereotactic ablative body radiotherapy (SABR) with conventional radiotherapy for early stage lung cancer has been conducted in Australia and New Zealand under the auspices of the TransTasman Radiation Oncology Group (NCT01014130). We report on the technical credentialing program as prerequisite for centres joining the trial. Methods: Participating centres were asked to develop treatment plans for two test cases to assess their ability to create plans according to protocol. Dose delivery in the presence of inhomogeneity and motion was assessed during a site visit using a phantom with moving inserts. Results: Site visits for the trial were cond..
View full abstractRelated Projects (1)
Grants
Funding Acknowledgements
The trial TROG 09.02 (CHISEL) was supported in Australia: Grant #1060822 was awarded through the Priority-driven Collaborative Cancer Research Scheme and funded by Radiation Oncology and Optometry Section of the Australian Government Department of Health, with the assistance of Cancer Australia. In New Zealand we would like to acknowledge The Cancer Society of New Zealand and the Genesis Oncology Trust. We would also like to acknowledge the support of the technical aspects of the study through the Gross Foundation. Parts of this work was presented at the IASLC 18th World Conference on Lung Cancer in Yokohama October 15 to 18, 2017. Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel) a Phase III clinical trial on Stereotactic Ablative Body Radiotherapy of early stage lung cancer.